Oral Anticoagulants Preference in Hospitalized Patients with Acute Deep Vein Thrombosis or Non-Valvular Atrial Fibrillation

被引:0
|
作者
Vesa, Stefan Cristian [1 ]
Vlaicu, Sonia Irina [2 ]
Crisan, Sorin [3 ]
Sabin, Octavia [1 ]
Saraci, George [4 ]
Vacaras, Vitalie [5 ]
Popa, Daciana Elena [6 ]
Parcalab, Paula [7 ]
Donca, Valer Ioan [8 ]
Macarie, Antonia Eugenia [8 ]
Sava, Madalina [9 ]
Buzoianu, Anca Dana [1 ]
机构
[1] Iuliu Hatieganu Univ Med & Pharm, Dept Pharmacol Toxicol & Clin Pharmacol, Cluj Napoca 400337, Romania
[2] Iuliu Hatieganu Univ Med & Pharm, Dept Internal Med, Med Clin 1, Cluj Napoca 400337, Romania
[3] Iuliu Hatieganu Univ Med & Pharm, Dept Internal Med, Med Clin 5, Cluj Napoca 400337, Romania
[4] Univ Med & Pharm, Grad Iuliu Hatieganu Fac Med, Cluj Napoca 400337, Romania
[5] Iuliu Hatieganu Univ Med & Pharm, Dept Neurol, Cluj Napoca 400012, Romania
[6] Niculae Stancioiu Heart Inst, Dept Cardiol, Cluj Napoca 400001, Romania
[7] Prof Dr Ion Chiricut Oncol Inst, Cluj Napoca 400010, Romania
[8] Iuliu Hatieganu Univ Med & Pharm, Dept Geriatr Gerontol, Cluj Napoca 400139, Romania
[9] Emergency Cty Hosp, Dept Dermatol, Oradea 410032, Romania
关键词
atrial fibrillation; deep vein thrombosis; anticoagulant choice; direct oral anticoagulants; vitamin K antagonists;
D O I
10.3390/healthcare8040404
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
(1) Aim: The aim of this study was to assess the preferences of oral anticoagulants (OA) in patients diagnosed with deep vein thrombosis (DVT) of lower limbs or non-valvular atrial fibrillation (AF) requiring anticoagulation for medium/long term. (2) Materials and methods: the study included consecutive patients admitted with a diagnosis of either acute DVT of lower limbs (without signs of pulmonary embolism) or non-valvular AF who required oral anticoagulation, in a time frame of 18 months from January 2017 until June 2018. The following data were recorded: demographic variables, comorbidities (ischemic heart disease, arterial hypertension, heart failure, stroke, peripheral artery disease, diabetes mellitus, obesity), type and dose of OA (acenocoumarol, dabigatran, apixaban, rivaroxaban), complications due to the use of OA. (3) Results: AF patients were older and had considerably more cardiovascular comorbidities than DVT patients. Vitamin K antagonists (VKA) were more likely to be administered in patients with AF, as they had indication for indefinite anticoagulation. VKA were more frequently prescribed in patients with ischemic heart disease, heart failure, and diabetes compared with DVT patients. Moreover, complications related to OA use were more frequent in the VKA group. Almost half of patients with acute DVT (48.5%) were treated with direct OA (DOAC) rather than VKA, and only a quarter of AF patients (24.8%) were treated with DOACs.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Willingness to Pay for Novel Oral Anticoagulants in Non-Valvular Atrial Fibrillation and Deep Vein Thrombosis Patients
    Lau, K. T.
    Poh, T. E.
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 249 : S42 - S43
  • [2] Novel oral anticoagulants in non-valvular atrial fibrillation
    Potpara, Tatjana S.
    Lip, Gregory Y. H.
    [J]. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2013, 26 (02) : 115 - 129
  • [3] New oral anticoagulants in non-valvular atrial fibrillation
    Francia P.
    Adduci C.
    Santini D.
    Musumeci B.
    Tocci G.
    [J]. High Blood Pressure & Cardiovascular Prevention, 2013, 20 (2) : 53 - 60
  • [4] Oral anticoagulants in diabetic and nondiabetic patients with non-valvular atrial fibrillation
    Derosa, G.
    Raddino, R.
    Gavazzoni, M.
    Pasini, G.
    Gaudio, G.
    Maggi, A.
    D'Angelo, A.
    Ragonesi, P. D.
    Brunetti, N.
    De Gennaro, L.
    Cattaneo, M.
    Maffioli, P.
    [J]. EUROPEAN HEART JOURNAL, 2018, 39 : 1409 - 1409
  • [5] Choice of oral anticoagulants in older patients with non-valvular atrial fibrillation
    Jolobe, Oscar M. P.
    [J]. BRITISH JOURNAL OF HOSPITAL MEDICINE, 2017, 78 (07) : 416 - 416
  • [6] Novel oral anticoagulants in acute ischemic stroke with non-valvular atrial fibrillation
    Teo, K. C.
    Chan, K. H.
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 1110 - 1111
  • [7] New anticoagulants in patients with non-valvular atrial fibrillation
    Zellerhoff, S.
    Lewalter, T.
    Eckardt, L.
    Treszl, A.
    Wegscheider, K.
    Breithardt, G.
    [J]. NERVENHEILKUNDE, 2012, 31 (11) : 813 - 820
  • [8] ORal anticoaGulants in diAbetic and Nondiabetic patients with nOn-valvular atrial fibrillatioN (ORGANON)
    Derosa, Giuseppe
    Rizzo, Manfredi
    Brunetti, Natale Daniele
    Raddino, Riccardo
    Gavazzoni, Mara
    Pasini, Gianfranco
    Gaudio, Giovanni
    Maggi, Antonio
    D'Angelo, Angela
    De Gennaro, Luisa
    Maffioli, Pamela
    [J]. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2023, 37 (08)
  • [9] Emerging oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation
    Destephan, C.
    Waller, A. H.
    Patel, R. J.
    Dhruvakumar, S.
    Mazza, V.
    Gerula, C.
    Maher, J.
    Kaluski, E.
    [J]. MINERVA CARDIOANGIOLOGICA, 2012, 60 (04): : 425 - 431
  • [10] Indirect Comparisons of the New Oral Anticoagulants in Patients with Non-Valvular Atrial Fibrillation
    Zolfaghari, Shabnam, Jr.
    Harenberg, Job
    Marx, Svetlana
    Wehling, Martin
    [J]. BLOOD, 2012, 120 (21)